Navigation Links
Amgen Announces 2013 Third Quarter Dividend
Date:7/26/2013

THOUSAND OAKS, Calif., July 26, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the third quarter of 2013. The dividend will be paid on Sept. 6, 2013, to all stockholders of record as of the close of business on Aug. 16, 2013. 

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2012, and in any subsequent periodic reports on Form 10-Q and Form 8-K.  Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and r
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have an impermeable ... devices now have an operator control device that will increase healthcare worker safety ...
(Date:6/30/2015)... ... June 30, 2015 , ... Park Systems ... advanced scientific research into new classes of Nanoscale Graphene-based materials poised to revolutionize ... 'the wonder material of the 21st Century' by the researchers who were awarded ...
(Date:6/30/2015)... ... 2015 , ... With its latest polyacrylonitrile (PAN) membrane, Sterlitech ... flow rates in comparison to nylon or polyethersulfone (PES). Its unique nanofiber ... liquid flow while trapping particulates as small as 0.2 micron in width. , ...
(Date:6/30/2015)... , June 30, 2015  Custom Computer Specialists, ... today that they are silver sponsors of the Primary ... PCDC sponsor, Custom is lending their support of PCDC,s ... communities. Since its founding in 1993, PCDC ... primary care area.  PCDC has financed over 100 completed ...
Breaking Biology Technology:Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4New Nanofiber Membrane Provides Fast, Efficient Filtration 2Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2
... SAN DIEGO, May 17, 2011 Verenium Corporation (Nasdaq: ... focused on the development and commercialization of high-performance enzymes, ... by MDB Capital Group at the second annual Bright ...  The Bright Lights Conference is the only conference with ...
... Life Technologies Corporation (NASDAQ: LIFE ... of Gibco® Freedom™ Cell Line Development Kits , a ... media and protocols to bring simplicity and flexibility, eliminating up ... drug development.  These kits make it easier and faster to ...
... May 16, 2011 Masimo ... from a new study published in the American ... hemoglobin (SpHb®) monitoring correlates strongly with invasive laboratory hemoglobin ... and critical care setting and may potentially decrease the ...
Cached Biology Technology:Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 2Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 3Verenium Receives CLARUS Award at MDB Capital's Bright Lights Conference 2011 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 2Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 3Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 4Life Technologies and ProBioGen AG Announce Freedom™ Cell Line Development Royalty-Free Kits To Advance Early Stage Biologic Drug Production 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 2New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 3New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 4New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 5New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care 6
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... drinking, an activity that many young people engage in, ... do a better job of controlling overall alcohol usage, ... Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj110029.pdf ... sale and consumption of alcohol, we need a national ...
... Calif. Researchers at the Stanford University School of ... supporting the use of platelet-rich plasma as a promising ... The findings were published online in Cardiovascular ... Sixth International Conference on Cell Therapy for Cardiovascular Disease ...
... 17, 2011 Eurofins MWG Operon, international market leader and ... supply DNA sequencing services to the Research Councils UK Shared ... to 3 years, and builds on a 5-year relationship developed ... to the Research Councils. RCUK SSC Ltd has ...
Cached Biology News:RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks 2
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Biology Products: